$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515377139 Filed on November 13, 2015

Income Statement

Concept	2015 Q3	2014 Q3
Revenue	$7.151M	$6.654M
YoY Change	7.47%	14.63%
Cost Of Revenue	$2.568M	$1.772M
YoY Change	44.92%	-29.18%
Gross Profit	$4.583M	$4.882M
YoY Change	-6.12%	47.81%
Gross Profit Margin	64.09%	73.37%
Selling, General & Admin	$5.423M	$3.729M
YoY Change	45.43%	25.68%
% of Gross Profit	118.33%	76.38%
Research & Development	$2.698M	$1.036M
YoY Change	160.42%	55.09%
% of Gross Profit	58.87%	21.22%
Depreciation & Amortization	$220.0K	$130.0K
YoY Change	69.23%	8.33%
% of Gross Profit	4.8%	2.66%
Operating Expenses	$10.34M	$5.261M
YoY Change	96.62%	-14.27%
Operating Profit	-$3.193M	$1.393M
YoY Change	-329.22%	-519.58%
Interest Expense	$251.0K	-$540.0K
YoY Change	-146.48%	8.0%
% of Operating Profit		-38.77%
Other Income/Expense, Net	-$45.00K	$355.0K
YoY Change	-112.68%	-35600.0%
Pretax Income	-$3.489M	$1.213M
YoY Change	-387.63%	-246.14%
Income Tax	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$3.489M	$1.213M
YoY Change	-387.63%	-246.14%
Net Earnings / Revenue	-48.79%	18.23%
Basic Earnings Per Share	-$0.29	$0.13
Diluted Earnings Per Share	-$0.29	$0.12
COMMON SHARES
Basic Shares Outstanding	11.89M	9.280M
Diluted Shares Outstanding	11.89M	11.22M

Balance Sheet

Concept	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.00M	$39.00M
YoY Change	-12.82%
Cash & Equivalents	$33.95M	$39.05M
Short-Term Investments
Other Short-Term Assets	$1.000M	$700.0K
YoY Change	42.86%
Inventory	$814.0K	$496.0K
Prepaid Expenses
Receivables	$2.200M	$1.700M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$37.97M	$42.01M
YoY Change	-9.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.571M	$2.049M
YoY Change	25.48%
Goodwill	$12.01M	$12.01M
YoY Change	0.0%
Intangibles	$6.650M	$6.650M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$21.37M	$20.85M
YoY Change	2.5%
TOTAL ASSETS
Total Short-Term Assets	$37.97M	$42.01M
Total Long-Term Assets	$21.37M	$20.85M
Total Assets	$59.34M	$62.86M
YoY Change	-5.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.949M	$1.036M
YoY Change	88.13%
Accrued Expenses	$4.800M	$2.600M
YoY Change	84.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.594M	$5.798M
YoY Change	-38.01%
Total Short-Term Liabilities	$10.45M	$11.12M
YoY Change	-5.97%
LONG-TERM LIABILITIES
Long-Term Debt	$12.13M	$6.930M
YoY Change	74.96%
Other Long-Term Liabilities	$28.00K	$3.800M
YoY Change	-99.26%
Total Long-Term Liabilities	$12.15M	$6.930M
YoY Change	75.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.45M	$11.12M
Total Long-Term Liabilities	$12.15M	$6.930M
Total Liabilities	$25.44M	$21.82M
YoY Change	16.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$168.3M	-$159.4M
YoY Change	5.62%
Common Stock	$12.00K	$12.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.90M	$41.04M
YoY Change
Total Liabilities & Shareholders Equity	$59.34M	$62.86M
YoY Change	-5.6%

Cashflow Statement

Concept	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$3.489M	$1.213M
YoY Change	-387.63%	-246.14%
Depreciation, Depletion And Amortization	$220.0K	$130.0K
YoY Change	69.23%	8.33%
Cash From Operating Activities	-$3.030M	-$3.660M
YoY Change	-17.21%	-321.82%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	-$170.0K
YoY Change	129.41%	750.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$30.00K
YoY Change	-100.0%
Cash From Investing Activities	-$390.0K	-$200.0K
YoY Change	95.0%	900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	480.0K	35.04M
YoY Change	-98.63%	-175300.0%
NET CHANGE
Cash From Operating Activities	-3.030M	-3.660M
Cash From Investing Activities	-390.0K	-200.0K
Cash From Financing Activities	480.0K	35.04M
Net Change In Cash	-2.940M	31.18M
YoY Change	-109.43%	1836.65%
FREE CASH FLOW
Cash From Operating Activities	-$3.030M	-$3.660M
Capital Expenditures	-$390.0K	-$170.0K
Free Cash Flow	-$2.640M	-$3.490M
YoY Change	-24.36%	-308.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11902363	shares
CY2014Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	239000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39048000
CY2015Q1	us-gaap	Share Price SharePrice	5.56
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031804	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
CY2015Q2	us-gaap	Share Price SharePrice	6.48
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1510479	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100133900	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.05
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11892518	shares
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2192000
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	33903000
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Share Price SharePrice	4.23
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1510479	shares
CY2015Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2331000
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	500000
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11892518	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12125000
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2015Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	431000
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202213000
CY2015Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	244000
CY2015Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	618000
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1490000
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	3594000
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	136000
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1949000
CY2015Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	618000
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168322000
CY2015Q3	us-gaap	Liabilities Liabilities	25439000
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59342000
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	724000
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	12000
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10454000
CY2015Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	252000
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2015Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	76000
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3400000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	961000
CY2015Q3	us-gaap	Assets Assets	59342000
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6650000
CY2015Q3	us-gaap	Inventory Net InventoryNet	814000
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	147000
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2571000
CY2015Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	2241000
CY2015Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	341000
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	473000
CY2015Q3	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent	170000
CY2015Q3	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	413000
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	127000
CY2015Q3	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	185000
CY2015Q3	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	144000
CY2015Q3	us-gaap	Assets Current AssetsCurrent	37969000
CY2015Q3	us-gaap	Goodwill Goodwill	12005000
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	960000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33954000
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	629151	shares
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	834000
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	881328	shares
CY2015Q3	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	523000
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	8.13
CY2015Q3	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Non Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent	177000
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	525000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5128000
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11803970	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11803970	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1616000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	463000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1684000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41298000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5451000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	273000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200661000
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	202000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1074000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1684000
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5961000
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	505000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1128000
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1074000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159375000
CY2014Q4	us-gaap	Assets Assets	61141000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6650000
CY2014Q4	us-gaap	Liabilities Liabilities	19843000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61141000
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	471000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11135000
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	241000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	70000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25000
CY2014Q4	us-gaap	Inventory Net InventoryNet	686000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	147000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1968000
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2687000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	277000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	40346000
CY2014Q4	us-gaap	Goodwill Goodwill	12005000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	542000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36431000
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	409000
CY2014Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	318000
CY2014Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	54000
CY2014Q4	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	146000
CY2014Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	144000
CY2014Q4	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent	76000
CY2014Q4	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Non Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent	11000
CY2015Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	20000000
CY2015Q1	cdna	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	90000
CY2014Q3	cdna	Sale Of Stock Pursuant To Exercise Of Underwriters Over Allotment Option SaleOfStockPursuantToExerciseOfUnderwritersOverAllotmentOption	220000	shares
CY2015Q1	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0200	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	350000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2628000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	179614	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0176	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	780956	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3973622	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4230	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8298903	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3798559	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	333000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	347108	shares
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3230000
	us-gaap	Net Income Loss NetIncomeLoss	786000
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	364000
	us-gaap	Revenues Revenues	19354000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-118000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1727000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	406000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	209000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	19145000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3716000
	us-gaap	Operating Income Loss OperatingIncomeLoss	821000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22000
	us-gaap	Licenses Revenue LicensesRevenue	31000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	192000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-521000
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	1000
	us-gaap	Royalty Revenue RoyaltyRevenue	166000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-120000
	us-gaap	Embedded Derivative Gain On Embedded Derivative EmbeddedDerivativeGainOnEmbeddedDerivative	239000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-714000
	us-gaap	Reimbursement Revenue ReimbursementRevenue	16000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	912000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	461000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1500000
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4982000
	us-gaap	Share Based Compensation ShareBasedCompensation	350000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	15000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4837000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	792000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	321000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	33920000
	us-gaap	Operating Expenses OperatingExpenses	18533000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-739000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	37287000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2548000
	us-gaap	Cost Of Services CostOfServices	6337000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1276000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6087000
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	17000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	39246000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	204000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-2507000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	354000
	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	-1500000
	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	26000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1028000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5776000
	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	29844	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2196875	shares
	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2016-01-01
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The Company agreed to issue to the lender detachable warrants to purchase shares of the Company's common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-12-01
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Concentrations of Credit Risk and Other Risks and Uncertainties</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the nine months ended September 30, 2015 and 2014, approximately 50% of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At September 30, 2015 and December 31, 2014 approximately 34% and 78%, respectively, of accounts receivable was from Medicare. At September 30, 2015, approximately 16% of accounts receivable was from Aetna. No other payer represented more than 10% of accounts receivable at September 30, 2015 and December 31, 2014.</p> </div>
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-456000
	us-gaap	Line Of Credit Facility Initiation Date1 LineOfCreditFacilityInitiationDate1	2015-01-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4074	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	CareDx, Inc.
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11846921	shares
	us-gaap	Default Longterm Debt Description Of Violation Or Event Of Default DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault	Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11846921	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.63
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Collaboration and License Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p> </div>
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities as applicable, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates.</p> </div>
	dei	Trading Symbol TradingSymbol	CDNA
	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement.
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
	us-gaap	Embedded Derivative Gain On Embedded Derivative EmbeddedDerivativeGainOnEmbeddedDerivative	0
	us-gaap	Net Income Loss NetIncomeLoss	-8945000
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8945000
	us-gaap	Revenues Revenues	21496000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8945000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Name NewAccountingPronouncementOrChangeInAccountingPrincipleName	ASU 2015-03
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1123000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	11451000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1334000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	349000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	21147000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7469000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	129000
	us-gaap	Licenses Revenue LicensesRevenue	0
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-446000
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	41000
	us-gaap	Royalty Revenue RoyaltyRevenue	275000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	393000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	15625000
	us-gaap	Share Based Compensation ShareBasedCompensation	1028000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	203000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6453000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	204000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	699000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2477000
	us-gaap	Operating Expenses OperatingExpenses	28965000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1123000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4422000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6629000
	us-gaap	Cost Of Services CostOfServices	7786000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-456000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	45000
CY2013Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	467000
	cdna	Percentage Of Default Interest Payment PercentageOfDefaultInterestPayment	0.05	pure
	cdna	Prepayment Penalty PrepaymentPenalty	0	pure
	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	115000
	cdna	Number Of Commercial Tests NumberOfCommercialTests	1	CommercialTests
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P7Y4M2D
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	5.52
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8553000
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	508000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	791000
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	11000
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	575000
	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	0
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P9Y1M6D
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	163000
	cdna	Description Of Agreement Expected Expiration Year DescriptionOfAgreementExpectedExpirationYear	The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	250000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	344000
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	387500
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	503000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1393000
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	0
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11219377	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	371273	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9279649	shares
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	355000
CY2014Q3	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	0
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	49000
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-120000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1213000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityPeriodIncreaseDecrease	-539000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1464000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	2552000
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	250000
CY2012	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1000000
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	8663	shares
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	48000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	11628	shares
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	75000
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	122142	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0205	pure
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	780956	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	1446313	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4381	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	1213000
CY2014Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	231000
CY2014Q3	us-gaap	Revenues Revenues	6654000
CY2014Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0
CY2014Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-535000
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	53000
CY2014Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	6601000
CY2014Q3	us-gaap	Reimbursement Revenue ReimbursementRevenue	0
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1324000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014Q3	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	0
CY2014Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1753000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	5261000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1036000
CY2014Q3	us-gaap	Cost Of Services CostOfServices	1772000
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3489000
CY2014Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1276000
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	165000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1976000
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0190	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	55450	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	9553	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2196875	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.81
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3910	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.36
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11890057	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	558578	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.94
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11890057	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.81
CY2015Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23284	shares
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-3489000
CY2015Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2015Q3	us-gaap	Revenues Revenues	7151000
CY2015Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-251000
CY2015Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	144000
CY2015Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	7007000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3193000
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	0
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-45000
CY2015Q3	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	8000
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	96000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3489000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2062000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	10344000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2698000
CY2015Q3	us-gaap	Cost Of Services CostOfServices	2568000
CY2015Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-345000
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	336000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3361000
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	40000
CY2015Q3	cdna	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	12.40
CY2015Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	1169

Files In Submission

Name	View Source	Status
0001193125-15-377139-index-headers.html	Edgar Link	pending
0001193125-15-377139-index.html	Edgar Link	pending
0001193125-15-377139.txt	Edgar Link	pending
0001193125-15-377139-xbrl.zip	Edgar Link	pending
cdna-20150930.xml	Edgar Link	completed
cdna-20150930.xsd	Edgar Link	pending
cdna-20150930_cal.xml	Edgar Link	unprocessable
cdna-20150930_def.xml	Edgar Link	unprocessable
cdna-20150930_lab.xml	Edgar Link	unprocessable
cdna-20150930_pre.xml	Edgar Link	unprocessable
d63461d10q.htm	Edgar Link	pending
d63461dex311.htm	Edgar Link	pending
d63461dex312.htm	Edgar Link	pending
d63461dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2015 Q3 Form 10-Q Financial Statement

#000119312515377139 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2015 Q3 Form 10-Q Financial Statement

#000119312515377139 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna